Unknown

Dataset Information

0

IRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.


ABSTRACT: Isoliquiritigenin (ISL), a natural anti-breast cancer dietary compound, has poor delivery characteristics and low bioavailability. In order to promote the therapeutic outcome of ISL, a tumor-targeting lipid-polymer hybrid nanoparticle (NP) system modified by tumor-homing iRGD peptides has been developed. The hybrid NPs were prepared by a modified single-step nanoprecipitation method to encapsulate ISL. iRGD peptides were anchored on the surface by a postinsertion method (ISL-iRGD NPs). The stable lipid-polymer structure of ISL-iRGD NPs, with high encapsulation and loading efficiency, was confirmed. Compared to free ISL and non-iRGD-modified counterparts, ISL-iRGD NPs showed higher cytotoxicity and cell apoptosis against the different type of breast cancer cells. This was attributable to higher cellular accumulation mediated by the iRGD-integrin recognition and the nanoscale effect. More importantly, based on the active tumor-tissue accumulation by iRGD peptides and the prolonged in vivo circulation by the stealth nanostructure, ISL-iRGD NPs displayed higher tumor-growth inhibition efficiency in 4T1-bearing breast-tumor mouse models. Therefore, the constructed iRGD modified lipid-polymer hybrid NPs would provide a promising drug-delivery strategy to improve ISL in anti-breast cancer efficacy.

SUBMITTER: Gao F 

PROVIDER: S-EPMC5459978 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6213168 | biostudies-other
| S-EPMC7081530 | biostudies-literature
| S-EPMC8372442 | biostudies-literature
| S-EPMC10302493 | biostudies-literature
| S-EPMC10504175 | biostudies-literature
| S-EPMC8383308 | biostudies-literature
| S-EPMC6401401 | biostudies-literature
| S-EPMC4077924 | biostudies-literature
| S-EPMC7523570 | biostudies-literature
| S-EPMC4977227 | biostudies-other